Dark

Check out our API

ULTI
REX IncomeMax Option Strategy ETF
stock NASDAQ ETF

At Close

Jul 2, 2026 3:45:36 PM EDT

10.47USD-4.384%(-0.48)92,393

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 1, 2026 9:25:30 AM EDT

11.80USD+1.462%(+0.17)0

After-hours

Jul 1, 2026 4:32:30 PM EDT

11.01USD+0.548%(+0.06)0

Overview HistoricalExchangesShortsNews

Dec 15, 2021

02:00AM EST -- Study assesses impact of UV1 in ovarian cancer maintenance care -- Addresses unmet medical need among BRCA-negative ovarian cancer patients -- Enrollment of 184 patients to be coordinated through NSGO-CTU and ENGOT GlobeNewswire Inc

Dec 2, 2021

01:00PM EST -- Designation covers UV1 in Metastatic Melanoma as sole agent or part of combination -- Seven-year market exclusivity after regulatory approval, if received GlobeNewswire Inc

Nov 11, 2021

02:00AM EST Ultimovacs ASA: Third quarter 2021 result presentation GlobeNewswire Inc

Nov 9, 2021

08:00AM EST -- UV1 vaccine combined with ipilimumab induced immune responses in 91% of melanoma patients -- Immune responses persist and are detectable up to 5 years GlobeNewswire Inc

Oct 26, 2021

10:48AM EDT -- Fifth Phase II trial of UV1 in cancer, and largest disease category to date -- UV1 will be investigated in combination with the standard-of-care pembrolizumab -- Expected data read-out by end of 2024 GlobeNewswire Inc

Oct 21, 2021

02:05AM EDT -- UV1 as add-on therapy to checkpoint inhibitors awarded Fast Track designation -- Provides for potentially expedited review of UV1 -- Ultimovacs to host webcast at 13.00 CET Thursday, 21 October 2021 GlobeNewswire Inc

Oct 13, 2021

02:34AM EDT Ultimovacs Announces Positive 24-month Follow-up Data from Phase I GlobeNewswire Inc

Oct 1, 2021

06:35AM EDT -- First patient in second cohort dosed with 400 g of TET vaccine -- DSMB found no safety concerns for first cohort of three patients at 40 g dose GlobeNewswire Inc

Aug 20, 2021

02:05AM EDT Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2021 results today. A presentation by the Company's management team will take place today on a webcast at 09:00 CEST. GlobeNewswire Inc

Aug 12, 2021

01:50AM EDT -- Cohort 2 showed 60% objective response rate, 30% complete response rate -- 90% overall survival rate at 12 months follow-up -- Cohort 2 results reinforce results seen in cohort 1 -- Good safety and tolerability profile supports use of UV1 in combination treatments GlobeNewswire Inc

Aug 11, 2021

11:05AM EDT Ultimovacs ASA (Ultimovacs) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2021 results on Friday 20 August 2021. GlobeNewswire Inc

Aug 5, 2021

02:05AM EDT -- Study will assess the benefit of combining UV1 with standard of care pembrolizumab -- Topline data expected in 2023 GlobeNewswire Inc

Jul 5, 2021

03:40PM EDT Ultimovacs Announces Review Article Highlighting Telomerase-based GlobeNewswire Inc

Jun 4, 2021

09:05AM EDT -- UV1/pembrolizumab results in 30% complete responses plus 30% partial responses -- Good safety and tolerability profile supports expanded Phase II combination program -- Data highlighted at ASCO in poster presentation GlobeNewswire Inc

Jun 1, 2021

08:00AM EDT Ultimovacs Announces Publication in The Journal of Translational GlobeNewswire Inc

May 19, 2021

04:56PM EDT -- UV1/pembrolizumab results in 30% complete responses plus 30% partial responses -- Good safety and tolerability profile supports use of UV1 in combination treatments -- Data to be presented at ASCO and abstract to be discussed in webcast on May 20, 2021 GlobeNewswire Inc

Share